JP2006522806A - 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ - Google Patents

細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ Download PDF

Info

Publication number
JP2006522806A
JP2006522806A JP2006509328A JP2006509328A JP2006522806A JP 2006522806 A JP2006522806 A JP 2006522806A JP 2006509328 A JP2006509328 A JP 2006509328A JP 2006509328 A JP2006509328 A JP 2006509328A JP 2006522806 A JP2006522806 A JP 2006522806A
Authority
JP
Japan
Prior art keywords
cell
dsrna
cells
molecular weight
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522806A5 (enExample
Inventor
スミス，ダン
ボット，エイドリアン
Original Assignee
マルチセル・イミュノセラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マルチセル・イミュノセラピューティクス，インコーポレイテッド filed Critical マルチセル・イミュノセラピューティクス，インコーポレイテッド
Publication of JP2006522806A publication Critical patent/JP2006522806A/ja
Publication of JP2006522806A5 publication Critical patent/JP2006522806A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006509328A 2003-03-26 2004-03-25 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ Pending JP2006522806A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45774503P 2003-03-26 2003-03-26
US49778403P 2003-08-26 2003-08-26
PCT/US2004/009261 WO2004087877A2 (en) 2003-03-26 2004-03-25 Selected rna motifs to include cell death and/or apoptosis

Publications (2)

Publication Number Publication Date
JP2006522806A true JP2006522806A (ja) 2006-10-05
JP2006522806A5 JP2006522806A5 (enExample) 2007-05-17

Family

ID=33135068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509328A Pending JP2006522806A (ja) 2003-03-26 2004-03-25 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ

Country Status (7)

Country Link
US (2) US20060172959A1 (enExample)
EP (1) EP1613775B1 (enExample)
JP (1) JP2006522806A (enExample)
CN (1) CN1795274A (enExample)
AU (1) AU2004225480A1 (enExample)
CA (1) CA2520181A1 (enExample)
WO (1) WO2004087877A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
US20080138431A1 (en) * 2005-03-02 2008-06-12 James Edward Eyles Pharmaceutical Composition
WO2009130616A2 (en) 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
CA2789847A1 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2014165296A1 (en) * 2013-03-12 2014-10-09 Multicell Immunotherapeutics, Inc. Methods and formulations to achieve tumor targeted double stranded rna mediated cell death

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
WO2002055692A2 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US508386A (en) * 1893-11-07 hayworth
US5906980A (en) * 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
US5683986A (en) * 1987-08-12 1997-11-04 Hemispherx Biopharma Inc. Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
US5593973A (en) * 1987-09-04 1997-01-14 Hemispherx Biopharma Inc. Treatment of viral hepatitis with mismatched dsRNA
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
WO1990009804A1 (en) * 1989-02-24 1990-09-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
ZA908037B (en) * 1989-10-11 1991-09-25 Hem Res Inc Protection from shock subsequent to injury by double-standed rnas
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
HU221385B1 (en) * 1994-07-13 2002-09-28 Chugai Pharmaceutical Co Ltd Reconstituted human antibody against human interleukin-8
DK0772619T4 (da) * 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
GB9501079D0 (en) * 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
AU3583797A (en) * 1996-06-28 1998-01-21 Regents Of The University Of California, The Enhancement of cancer cell death
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6777546B2 (en) * 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE60038189T2 (de) * 2000-05-25 2009-02-19 Fuji Xerox Co., Ltd. Toner und bilderzeugungsmethode
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
KR20050042032A (ko) * 2001-11-02 2005-05-04 세키스이가가쿠 고교가부시키가이샤 사이토카인 유도 재료 및 사이토카인 유도 용구
JP2005526778A (ja) 2002-03-15 2005-09-08 アストラル，インコーポレイテッド 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法
EP1556082A1 (en) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
CN101018567B (zh) * 2004-07-20 2011-07-27 先灵公司 表达Toll样受体的肿瘤细胞凋亡的诱导
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
WO2002055692A2 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung

Also Published As

Publication number Publication date
CA2520181A1 (en) 2004-10-14
US20090169571A1 (en) 2009-07-02
EP1613775B1 (en) 2012-08-29
WO2004087877A2 (en) 2004-10-14
WO2004087877A3 (en) 2005-06-16
US20060172959A1 (en) 2006-08-03
EP1613775A4 (en) 2009-10-21
CN1795274A (zh) 2006-06-28
AU2004225480A1 (en) 2004-10-14
EP1613775A2 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
Marshall et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions
AU776268B2 (en) Immunostimulant oligonucleotide
Nishikawa et al. Enhanced immunostimulatory activity of oligodeoxynucleotides by Y‐shape formation
CA2270345C (en) Immunostimulatory nucleic acid molecules
Wu et al. Necessity of oligonucleotide aggregation for toll-like receptor 9 activation
KR101862271B1 (ko) 비-코딩 면역조절 dna 구조체
JP2011200248A (ja) 安定化免疫調節オリゴヌクレオチド
KR20060040417A (ko) ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
JP2005237328A (ja) インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
AU2014205544B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP5481068B2 (ja) ＣｐＧオリゴデオキシヌクレオチドによって誘発される免疫応答を変化させる方法
US20090169571A1 (en) Selected ma motifs to include cell death and/or apoptosis
Hung et al. Upregulation of chemokine CXCL1/KC by leptospiral membrane lipoprotein preparation in renal tubule epithelial cells
Sen et al. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity
Qiao et al. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation
Sabbatucci et al. Toll-like receptor cross-talk in human monocytes regulates CC-chemokine production, antigen uptake and immune cell recruitment
Rodriguez et al. Immunostimulatory PyNTTTTGT oligodeoxynucleotides: structural properties and refinement of the active motif
AU2008201987A1 (en) Selected RNA motifs to include cell death and/or apoptosis
Peng et al. Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function
Duvanov Selection of oligonucleotides specific to chicken peripheral blood mononuclear cells in whole blood ex vivo system
Gray Regulation of Interferon Alpha Beta Induction and Dendritic Cell Function by CpG Oligodeoxynucleotides
Makiya Nishikawa et al. Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation
Heidegger Tissue-specific migration: The effect of innate immune activation on lymphocyte homing to the gastrointestinal tract
HK1161615A (en) Immunostimulatory nucleic acid molecules comprising gtcgtt motifs
HK1098499A (en) Immunostimulatory nucleic acid molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101019